LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q1 2024 Earnings Call Transcript

And if you look at it percentage-wise through the quarters, I think you get some good answers there. There is an FX topic that’s hurting us as we go through the rest of the year. And certainly, since last guide, I think it was like $1.1 million or so that FX has gone against us. So, our increase in guide is actually maybe a little bit more robust than it seems. We beat by, what, $1.7 million, $1.8 million in Q1 and now we’re given an extra up to $3 million and then really, it’s up to $4 million, $4.2 million because of that FX piece. So, I think we’re signaling that we feel more confident about the sales answer driven by ASPs and hospital cases and some of the good results in these individual product lines as well as the geographies that we talk about Thailand and Korea and other places that are sort of popping up and doing well also.

Daniel Stauder: That’s great. Thank you for the questions and congrats on the great quarter.

George LeMaitre: Thanks Daniel.

Operator: Thank you. Our next question or comment comes from the line of Michael Sarcone from Jefferies. Mr. Sarcone, your line is now open.

Michael Sarcone: Hi, good afternoon and thanks for taking my questions. The AMP said you’re getting 8%, I think J.J. said this year now, you’re expecting closer to 8% to 9%, really impressive. Just wanted to get a feel for how sustainable you think that level of price taking is as we look beyond 2024?

George LeMaitre: Right. So, Michael, I try to make a real point of not guiding past Q4 of 2024 here. But in sort of answer to your question as much as I can. I feel like we’re in about the sixth inning in a nine-inning baseball game. People have been asking this question a lot, and we’ve come back to that. We’re in the sixth inning of these price hikes.

Michael Sarcone: All right. Great, that’s helpful. Thank you. And then just a question around the ERP system you’ve talked about, you mentioned real-time reporting, financial processes and more sophisticated analytics, was wondering if you could speak to — does this help at all who sales force productivity in any way? And then on the expense side, are you going to be able to wring any expense efficiencies from some of the analytics you may be getting from the ERP system?

George LeMaitre: So, it’s a great question. And it’s a big project in Burlington, even though it doesn’t really poke out too much on calls like this. We have this very strong belief that better accounting leads to better decisions everywhere in your business. So, the answer to all of your questions is yes, we probably can watch the sales folks more closely. And yes, we can bring some efficiencies out of the operations we’ve never installed the program this big. We were still on sort of what I’ll call a Junior Varsity platform until February of this year. So, this is a big switch for us. We’re really excited about it. We all feel strongly that better accounting will lead to better decisions and better results for the company.

J.J. Pellegrino: Mike as an example, our analytics tool is homegrown. And the analytics tools homegrown by our IT folks who did a phenomenal job, and it does a really nice job of getting data to folks quickly in slicing and dicing but there’s an even better answer out there that Microsoft has been working on for the last 20 years. And so eventually, we’ll replace that analytics tool, and it will pump out even more sophisticated data and make it easier to get. Just one example, of how it might benefit us in the future.

Michael Sarcone: That’s helpful, J.J. Yes, I was going to say it’s impressive. There’s no shortage of companies that have sales force or commercial disruptions while they’re implementing larger ERP systems. Just one last one for me that I’ll squeeze in. Could you just give us an update on how things are going with Aziyo and how you’re thinking there?

Dave Roberts: Hey Mike, it’s Dave Roberts. Sure. Happy to. In Q1, we did about $1.25 million sales of Aziyo, which was right at the guidance sort of performed where we expected. That was down from the $1.5 million in Q4. And we don’t really guide on the product line going forward, but it had a good April, so we’ll see where it comes out. But I would say at a high level, it’s a little bit under what we expected when we signed the deal a year ago, but not too far under. And Q1 was the first quarter where Aziyo was on the LeMaitre reps commission plan. So, it’s still sort of early days at the moment.

Michael Sarcone: Got it. Thank you.

George LeMaitre: Thank you.

Operator: Thank you. Our next question or comment comes from the line of James Sidoti from Sidoti & Company. Mr. Sidoti, your line is now open.

Unidentified Analyst: Thank you. This is Alex on for Jim. Congrats on the quarter and thanks for taking questions. A couple of quick ones for me. We spoke about GLPs, effect on cardiovascular event reductions in the fall. It sounded like there wasn’t a meaningful effect. I just wanted to check in on that and see if that’s still helps.

George LeMaitre: Yes. Okay. Thanks for your question, Alex. It’s George. We have not seen anything in the whole sort of thing kind of came and went. From our perspective, sort of as a Wall Street [Indiscernible] we feel comfortable that our business proceeds with or without GLP. So, no effect up here.

Unidentified Analyst: Thanks for the update. Appreciate it. And I wanted to check in on the manufacturing operations. So, you guys had spoken about thinking of adding additional shifts or opening up another facility maybe in Burlington. Just wanted to check in on how you’re thinking about that these days.

George LeMaitre: Hi Alex, yes, okay. So look, it’s a bit of an old topic in some ways, which is we did this project called Small Ball about a year and a half ago, and instead of renting a new building, what we did as we went into one of our buildings, we carved out another 50% of clean room space. And that’s online, maybe about 12 months ago or so, and then we went and hired a lot of people for that. And we also hired a second shift. I would say, in a hopeful analysis, the better gross margin here is a little bit impacted by all that, but not exactly. So yes, we have a much bigger floor plate for manufacturing, and we also have second shift now. There’s really no constraints to manufacturing up here. I switch the topic a little bit.